Robin Roehm’s Post

Everyone will gain from this move from isolated excellence to collective acceleration. OpenFold3 + Apheris is setting a precedent for how AI and structural biology can evolve—securely, collaboratively, and at scale!

Thermo Fisher’s $9 Billion Leap: Redefining Clinical Insights Thermo Fisher is making another bold move acquiring Clario Holdings in a $9.4 billion deal that strengthens its position at the heart of clinical innovation. With Clario’s advanced endpoint data and analytics powering 70 % of U.S. drug approvals in the past decade, this acquisition bridges Thermo Fisher’s scientific hardware leadership with digital intelligence for faster, more informed trials. This isn’t just another billion-dollar acquisition it’s a signal that data has become the new molecule in drug development. https://lnkd.in/eZuYWazp #Biotech #MergersAndAcquisitions #ThermoFisher #Clario #ClinicalTrials #DigitalHealth #LifeSciences #PharmaInnovation

Federated learning has already proven that collaboration can happen without giving up data. Bristol Myers Squibb, Takeda, and Astex Pharmaceuticals joining OpenFold 3 is another strong signal in that direction. If pharma and AI companies start sharing models, architectures, and learned representations, we’ll accelerate discovery for everyone and patients will get new medicines faster. At Receptor.AI, we believe the future of drug discovery is collective, not competitive. #drugdiscovery #pharma #federatedlearning

🚀 Major Announcement in the Pharma & Clinical-Research World! 🚀 Excited to share that Thermo Fisher Scientific has entered into a definitive agreement to acquire Clario - a leading provider of endpoint-data solutions for clinical trials. A move that will meaningfully reshape the way pharma and biotech companies harness data, tech and insights. Here’s why this is such a big play: 1. Clario supports the collection, management and analysis of endpoint data from devices, sites and patients and has helped drive ~70% of FDA drug-approvals over the past decade. 2. The acquisition enables Thermo Fisher to deepen its digital & data-capability footprint, driving faster, smarter drug-development decisions for its customers. 3. Financially, the deal is immediately accretive to EPS and backed by an attractive synergy profile, highlighting how strategic, not just reactive, the move is. From my vantage in the outsourced services ecosystem, this signals several key implications: 👉 Expect smarter, more integrated solutions combining technology + data + clinical operations. 👉 Companies that want to remain competitive will need to partner with and hire for teams that understand this “end-to-end” paradigm (endpoint data, digital tools, global delivery). 👉 The bar for clinical insight and operational agility continues to rise, this transaction is a strong indicator of where the market is headed. Congratulations to both Thermo Fisher and Clario’s teams on this ambitious leap. Exciting times ahead for science, innovation and patient impact! #ThermoFisher #Clario #PharmaTech #ClinicalResearch #DigitalHealth #MergersAndAcquisitions #DrugDevelopment https://lnkd.in/enQEnBdA

Trust is the foundation of breakthrough science. For Scribe Therapeutics, building that trust meant ensuring scientists could focus on research, not spreadsheets, lost certifications, or equipment downtime. By consolidating processes and implementing CERDAAC, their Lab Ops team gained time back, earned respect across the organization, and created a system scientists and finance alike could rely on. Watch the case study to see how Scribe Therapeutics streamlined lab operations and strengthened confidence across their teams. #calibration #compliance #medtech #lifesciences #pharma #manufacturing #science

Thermo Fisher just made waves with a groundbreaking $9.4 billion acquisition of Clario Holdings, a major player in clinical trial data. This strategic move is not merely financial—it's a game-changer for drug development as we know it. By combining their lab services and contract research expertise with Clario's advanced data capabilities, Thermo Fisher is positioning itself at the forefront of the data-driven revolution in pharmaceuticals. As CEO Marc Casper noted, controlling end-point data shifts the conversation with regulators, insurers, and patients. The implications are massive: digitized, decentralized clinical trials could accelerate innovation, while AI reshapes drug discovery. However, will Thermo Fisher successfully integrate Clario's talent and technology, or will the cultural divide pose challenges? As we witness this pivotal moment in life sciences, one thing is clear—data is the new gold. Keep your eyes on this evolving landscape. #Pharmaceuticals #Innovation #DataScience

Lilly eyes Philly for a potential future site of its Gateway Labs model, in which it offers lab and office space and other resources for young life sciences companies. Philadelphia is a key biotech hub and the home of Lilly’s Avid Radiopharmaceuticals subsidiary, which is where the pharma got its chief scientific officer. #lilly #elililly #gatewaylabs #phillybiotech #philadelphiabiotech https://lnkd.in/gG66Rjeh

#SmallBiotechsBigDecisions dives into what investors really want from biotech CEOs. Listen to the full episode here: https://vist.ly/4bbu5 Claire Riches, VP of Clinical Solutions at Citeline, sits down with Alistair MacDonald, CEO of Worldwide Clinical Trials to explore why good science isn’t enough and how CEOs can build “Velcro” board relationships that drive funding and long-term success. Key insights include: ✔️ Clear execution plans and market definition ✔️ Data-driven confidence through AI and real-world evidence ✔️ CEO-board dynamics that foster trust and transparency ✔️ Refining your pitch to prove fundability 👀 Watch the full conversation: https://vist.ly/4bbu5 👂 Listen on the go: https://lnkd.in/gy2rm-w4 🔍 Explore all episodes: https://vist.ly/4bbu8 ———— Follow Citeline, the leading provider of drug, device, company, clinical trial, and market intelligence in the pharmaceutical and medtech markets.

We are delighted to welcome Campana & Schott as new members of the Pistoia Alliance. From their New York City base, Campana & Schott blend German precision with U.S. pace, partnering with pharmaceutical, biotech, and MedTech organizations to transform complex data into actionable insights, enhance portfolio decision-making, and drive adoption across R&D, Medical, Access, and Commercial functions. Their approach applies actionable FAIR data principles to scale AI solutions and reduce the time from data origination to breakthrough. As members of the Pistoia Alliance, Campana & Schott will contribute to advancing evidence-based FAIR assessment methods, interoperable ontology patterns, and practical implementation playbooks, supporting our shared mission to accelerate innovation and collaboration in life sciences R&D.

We’re honored to join the Pistoia Alliance and stand alongside industry leaders advancing FAIR data in life sciences. This strategic partnership strengthens our work with Anuj Uppal and further elevates our commitment to developing a robust FAIR Data Assessment offering for early R&D — grounded in both scientific rigor and real-world application. At Campana & Schott USA, we believe that bridging high standards of precision with a pragmatic, client-first mindset is essential. Together, we aim to help pharma and biotech organizations transform their data capabilities — to make R&D faster, more reliable, and more transparent. #FAIRData #LifeSciences #DataTransformation #DataInnovation #PistoiaAlliance